Interesting DXCM Put And Call Options For March 27th

DexCom (DXCM) option ideas: a $70 put trading with a $2.75 bid implies a net purchase basis of $67.25 (stock at $70.62) and a 57% probability of expiring worthless, representing a 3.93% return (28.70% annualized) if it does. On the call side, a $72 covered call with a $3.10 bid would cap sale at $72 and generate a 6.34% total return if called by the March 27 expiration, with a 49% chance of expiring worthless and a 4.39% (32.07% annualized) YieldBoost if it does. Implied volatilities are ~51% (put) and 53% (call) versus a 12‑month realized volatility of 45%, underscoring elevated option premiums for DXCM. Investors should weigh upside forgone on covered calls and the assignment risk on short puts against these yield-enhancing returns.

Analysis

Market structure: The immediate beneficiaries are option premium sellers and market-makers (collecting elevated IV of 51–53% vs realized ~45%), while directional long-only holders face capped upside from covered-call dynamics. The availability of $70 puts ($2.75) and $72 calls ($3.10) indicates dealer willingness to take on short-delta risk, implying neutral-to-mildly-bullish positioning into the Mar 27 expiry. Cross-asset effects are small but real: front-month option selling will reduce equity gamma, slightly muting intraday volatility; negligible direct impact on bonds/FX unless a major regulatory shock hits healthcare sector risk premia.

Risk assessment: Tail risks include an adverse FDA/regulatory ruling or a device safety recall that could trigger a >30% gap down (low probability, high impact) and force assignment of short puts. Near-term (days–weeks) risk is concentrated around Mar 27 expiry and any pre-expiry corporate/coverage headlines; medium-term (1–6 months) risks are reimbursement/competitive share shifts (Abbott Libre) that can compress growth. Hidden dependencies: assignment risk concentrates equity exposure among retail/option sellers; margin calls from concentrated short-put books could turbo-charge downside.

Trade implications: Favor short-dated premium-selling strategies sized conservatively: sell-to-open DXCM Mar27 $70 puts at $2.75 (net basis $67.25) sized to 1–2% portfolio notional per contract and ensure cash cover for assignment; plan exit if DXCM < $68 or IV rises >10 vol points (to >61%). If long equity, sell Mar27 $72 covered calls to harvest the 6.34% gross return to expiry; alternatively sell front-month calls and buy a 3–6 month call (calendar) to capture term-structure skew. Use protective put (e.g., Mar27 $65 buy) if unwilling to take assignment risk above a 5% loss threshold.

Contrarian angles: Consensus underestimates operational/regulatory jump risk — front-month IV may be underpriced for a material surprise; selling premium is attractive only if you can absorb assignment/25–35% drawdowns. Historical CGM episodes show 20–40% moves on reimbursement or competitive studies; crowded short-put positioning can flip into forced buying, so size and hard stop rules matter more than headline yield figures.

Key Decisions for Investors

• Sell-to-open DXCM Mar27 $70 put at $2.75 (collect $275 per contract) sized to no more than 1–2% of total portfolio notional (1 contract ≈ $7.06k exposure); hold cash to assign; close position if DXCM trades < $68 or implied vol > 61% (IV +10).
• If you already own DXCM, sell Mar27 $72 covered calls to realize ~6.34% to-expiry return but cap upside; hedge with a Mar27 $65 protective put if downside protection to -5% is required (cost-funded by reducing covered-call allocation).
• Implement a calendar/volatility trade: sell front-month (Mar) calls (e.g., $72) and buy 3–6 month calls to exploit front-month IV rich vs back-month; limit net delta to ±0.25 and close 3–5 days before earnings or any FDA/reimbursement events.
• Establish a pair-trade for 3-month horizon: long DXCM vs short ABT (dollar-neutral, 1% portfolio notional) to isolate CGM share re-acceleration while hedging broader healthcare beta; reassess after quarterly results or any FDA announcements.